Skip to content

Finished goods at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Danaher logo
DanaherDHR
Revvity logo
RevvityRVTY
Agilent Technologies logo
Agilent TechnologiesA
Charles River Laboratories logo
Charles River LaboratoriesCRL
Idexx Laboratories logo
Idexx LaboratoriesIDXX

Other financials

Income statement

See full
Revenue$619.8M-10.5%
Gross profit$263.8M-23.2%
Operating income-$31.8M-198%
Net income-$91.8M-623%
EPS (diluted)-$1.35-611%

Balance sheet

See full
Cash & equivalents$140.4M+10.4%
Total debt$3.1B+0.3%
Total equity$1.9B-38.2%
Total assets$5.6B-12.9%

Cash flow

See full
Operating cash flow-$33.0M-150%
CapEx$34.0M-39.5%
Free cash flow-$67.0M-813%

Valuation

See full
Market cap$832.61M-51.4%
Enterprise value$3.8B-20.1%
P/S0.3×-0.3×

Profitability

See full
Gross margin45%-2.0pp
Operating margin-37%-46.2pp
Net margin-45.6%-75.7pp
FCF margin13.8%

Returns & leverage

See full
Return on equity-49.9%-70.8pp
Debt / equity1.7×+0.6×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is QuidelOrtho Corporation's finished goods?
QuidelOrtho Corporation (QDEL) reported finished goods of $318.5M in Q1 2026.
How has QuidelOrtho Corporation's finished goods changed year-over-year?
QuidelOrtho Corporation's finished goods increased by 2.0% year-over-year, from $312.3M to $318.5M.
What is the long-term trend for QuidelOrtho Corporation's finished goods?
Over 2 years (2023 to 2025), QuidelOrtho Corporation's finished goods has grown at a -4.7% compound annual growth rate (CAGR), from $318.1M to $289M.
What does finished goods mean?
Completed products ready for sale, valued at the lower of cost or net realizable value.